Value is a concept that concerns all healthcare stakeholders.
A study found that cost-effectiveness and clinical-effectiveness measures often point to the same treatment protocol.
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
The IMS Institute for Healthcare Informatics says makers of cancer drugs will need more than data points for payers to see the value in their pricey new treatments.
A Pfizer poll shows patients rely on over-the-counter medications but need help finding the right treatment.
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
Four start-ups presented their business models to pharma executives during the MM&M Transforming Healthcare conference on Thursday in New York City.
Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
The patient journey concept needs a reboot, according to executives at the inaugural MM&M Transforming Healthcare conference.
A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.